Study Summary
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Interested in this trial?
Submit an InquiryInterventions
anti Tim-3/CD123 CAR-T cell therapyDRUG
Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Kailin Xu | Xuzhou | Jiangsu | China |